Start-ups developing brain-computer interfaces (BCIs), devices that connect the human nervous system directly with computers, have collectively attracted over $1 billion in funding this year, signaling growing investor confidence in a technology that promises to revolutionize medical treatment and human-computer interaction.
BCIs detect neural activity and translate it into digital commands, potentially restoring speech and movement to individuals affected by injury or disease. While the technology remains largely experimental, proponents believe it could eventually enable computers and artificial limbs to operate as seamless extensions of the human body.
Elon Musk’s Neuralink, founded a decade ago, leads the sector with more than $1.3 billion raised through seven funding rounds. However, numerous other start-ups worldwide are pursuing different approaches to BCI development. Precision Neuroscience, a New York-based company that recently implanted a device in patient Jasaun Knight during a brain cancer surgery, focuses on thin, flexible implants placed on the brain’s surface without penetrating it. Knight, who is among fewer than 200 people globally to receive such implants, described using the device to control a computer with his thoughts as “mind-blowing,” likening it to telekinesis.
The most advanced BCIs are invasive, involving surgical insertion of electrodes into or onto the brain for long-term use. Non-invasive alternatives, which place sensors on the scalp, avoid surgery but currently suffer from lower signal quality, limiting their ability to reliably translate thoughts into digital commands. Experts note that while non-invasive techniques hold promise, most venture capital is flowing into implantable devices due to their higher precision.
The industry’s growth is strongly supported by the U.S. venture capital market and a relatively responsive Food and Drug Administration. Several American companies including Synchron, Blackrock Neurotech, Axoft, and Merge Labs have benefited from this environment. Meanwhile, European start-ups such as CorTec in Germany, Onward Medical in the Netherlands, InBrain in Spain, and Neurosoft and Ability Neurotech in Switzerland combine strong engineering and neuroscience expertise but face challenges in securing large-scale funding and navigating fragmented regulatory and reimbursement systems. CorTec has chosen to conduct initial clinical trials in the United States, citing more established regulatory guidance.
China is emerging as a significant player following the government’s designation of BCIs as a strategic sector, aiming to establish multiple world-class companies by 2030. National and provincial investment funds, industrial hubs, and clinical trial support have fueled the growth of Chinese neurotechnology firms like NeuRexx in Shanghai. The country’s large patient population and regulatory backing are viewed as advantages in advancing BCI development.
Innovations are also focusing on two-way communication, or closed-loop stimulation, which not only reads brain signals but sends feedback to the nervous system. CorTec is among the companies developing such technology, with applications targeting stroke rehabilitation by stimulating motor cortex cells to improve function.
The integration of BCIs with prosthetics represents another promising frontier. Companies such as Open Bionics design artificial limbs equipped with sensors that pick up residual muscle movements and translate them into prosthetic control. Although these devices have improved dramatically, users still face limitations in dexterity and sensory feedback. Start-ups hope direct brain interfaces will bridge this gap, enabling more natural control and potentially restoring a sense of touch.
Though the sector’s investment climate has fluctuated, revenue growth in companies like Open Bionics—reported at a compound annual rate of 60 percent since 2018—demonstrates escalating commercial interest. As development continues, many in the field acknowledge that public expectations are influenced by portrayals in science fiction, while the technical challenges remain substantial. Nevertheless, researchers and entrepreneurs alike foresee a future in which brain-computer interfaces fundamentally change the interaction between humans and machines.